skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Canada Consults On Mandatory Reporting Of Device Incidents By Hospitals l Pharma Intelligence

 

Health Canada is inviting stakeholder feedback on a draft guideline that explains how hospitals can comply with recent changes in the regulation that make it mandatory for them to report medical device incidents (MDIs) and serious adverse drug reactions (ADRs) to the government within 30 calendar days.

Currently, only device and drug companies are required to report MDIs and/or serious ADRs, whereas reporting by health-care institutions and consumers is voluntary. In June, the Canadian government changed the Medical Device and Food and Drugs regulations, making it mandatory for hospitals to report these incidents because, it said, a potentially significant number of MDIs and serious ADRs go unreported.

The government believes the collection and assessment of this real-world information will help Health Canada better monitor the safety of therapeutic products once they are on the market.

The new draft guideline clarifies that if an MDI or serious ADR incident is documented within the hospital, then the hospital is required to report it to Health Canada regardless of whether the incident originated outside of a hospital setting or whether the patient was admitted to hospital or not.

Specifically, reporting is mandatory in relation to MDIs and serious ADRs that are "in a hospital’s control." This means that hospitals would be required to submit incidents documented by health-care professionals within their facilities, but would not be required to further investigate the event with the institution where the MDI/serious ADR originated. They are, however, encouraged to follow up the matter with the concerned other health-care institution, e.g., a nursing home, to obtain the required information to submit a more complete report.

Health Canada initially proposed that the mandatory reporting requirement should only apply to hospitals that provided acute-care services. (Also see "Canada Proposes 30-Day Limit For Hospitals To Report Safety Incidents With Devices" - Medtech Insight, 30 Jun, 2017.) It has since broadened the scope of the regulations to capture incidents from potentially important facilities, such as chronic-care and extended-care hospitals and mental-health facilities, where treatment of such reactions/incidents may occur.

Comments on the draft guideline will be accepted through Aug. 29.

From the editors of Scrip Regulatory Affairs

Read also

  • In Vivo: strategic insights for life sciences decision-maker...

    Pharma News and Healthcare Business Insights

    Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.

  • Medtech Insight: global medical technology news & analysis

    UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch

    BSI tackles Brexit issues head-on with aim to allay fears and bring clarity while UK regulator, MHRA, remains reticent to do so. Its messages are relevant for all doing business in the UK

    Topics Brexit

  • Scrip: industry news and insights

    Exploring Sanofi's Revamped IO Pipeline

    ByLucie Ellis

    In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.

    Topics Cancer

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: